Reticulon 3 deficiency ameliorates post-myocardial infarction heart failure by alleviating mitochondrial dysfunction

Bingchao Qi1, Tiantian Li1, Haixia Luo1

  • 1Department of Cardiology Tangdu Hospital Air Force Medical University Xi'an Shaanxi China.

Medcomm
|February 29, 2024
PubMed

Insights

Reticulon 3 (RTN3) drives heart failure (HF) after myocardial infarction (MI) by disrupting heat shock protein beta-1 (HSPB1) function. Targeting RTN3 offers a potential therapeutic strategy for HF and cardiovascular diseases.

Area of Science:

  • Cardiology
  • Molecular Biology
  • Biochemistry

Background:

  • Heart failure (HF) post-myocardial infarction (MI) involves complex molecular pathways.
  • Current interventions targeting individual pathological processes show limited clinical efficacy.
  • Identifying novel therapeutic targets is crucial for improving cardiac function after MI.

Purpose of the Study:

  • To investigate the role of reticulon 3 (RTN3) in the development of HF following MI.
  • To explore RTN3 as a potential therapeutic target for mitigating cardiac dysfunction.

Main Methods:

  • Utilized gain- and loss-of-function approaches in cellular and animal models.
  • Assessed cardiac function, molecular signaling pathways, and protein localization.
  • Correlated plasma RTN3 levels with cardiac function in human patients with acute MI.

Main Results:

  • RTN3 expression was elevated in human HF patients and in mice post-MI.
  • RTN3 overexpression impaired cardiac function, while RTN3 knockout alleviated MI-induced cardiac dysfunction.
  • RTN3 mediated heat shock protein beta-1 (HSPB1) translocation, leading to TLR4 elevation, mitochondrial dysfunction, and inflammation via TLR4/PGC-1α and TLR4/NFκB pathways.

Conclusions:

  • Reticulon 3 (RTN3) is identified as a critical mediator of cardiac dysfunction after MI.
  • Targeting RTN3 presents a promising therapeutic strategy for managing MI and associated cardiovascular diseases.